<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>60(1)</volume><submitter>Henrotin Y</submitter><funding>Tilman SA</funding><pubmed_abstract>&lt;h4>Context&lt;/h4>Osteoarthritis (OA) of the hand is a common painful musculoskeletal disorder with no cure. There is a need for an efficient and safe treatment to relieve OA pain.&lt;h4>Objective&lt;/h4>To investigate the effects of a &lt;i>Curcuma longa&lt;/i> and &lt;i>Boswellia serrata&lt;/i> food supplement in addition to standard care on hand pain.&lt;h4>Materials and methods&lt;/h4>This open-label, non-controlled, post-observational study was based on 232 patients suffering from hand pain with or without joint deformity. Patients received a medical prescription for a three-month treatment with a food supplement containing 89 mg of &lt;i>C. longa&lt;/i> dry extract, 120 mg of &lt;i>B. serrata&lt;/i> resin, and 1.8 µg vitamin D. Pain was evaluated on a 10-point visual analog scale (VAS). The number of painful hand joints, patient satisfaction, nonsteroidal anti-inflammatory drugs intake, and side effects were also recorded.&lt;h4>Results&lt;/h4>Baseline pain intensity (regression coefficient ± &lt;i>SE&lt;/i>: -0.19 ± 0.01, &lt;i>p&lt;/i> &lt; 0.0001) and the number of painful joints (regression coefficient ± &lt;i>SE&lt;/i>: -0.022 ± 0.0029, &lt;i>p&lt;/i> &lt; 0.0001) decreased significantly throughout the 3 months treatment period. NSAIDs intake and topical drug application were significantly decreased by 64% (&lt;i>p&lt;/i> &lt; 0.0001) and 79% (&lt;i>p&lt;/i> &lt; 0.0001) after 12 weeks, respectively. Only 3/239 (1.3%) patients reported side effects probably related to the product. 80.3% were satisfied with the treatment and 75.5% wished to continue treatment.&lt;h4>Conclusion&lt;/h4>This is the first clinical trial showing that &lt;i>C. longa&lt;/i> and &lt;i>B. serrata&lt;/i> resin can relieve symptoms in patients with hand osteoarthritis. The study provides useful information for the design of a clinical trial including a broader population.</pubmed_abstract><journal>Pharmaceutical biology</journal><pagination>2295-2299</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9704064</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>&lt;i>Curcuma longa&lt;/i> and &lt;i>Boswellia serrata&lt;/i> extract combination for hand osteoarthritis: an open-label pre-post trial.</pubmed_title><pmcid>PMC9704064</pmcid><pubmed_authors>Delisse G</pubmed_authors><pubmed_authors>Dierckxsens Y</pubmed_authors><pubmed_authors>Henrotin Y</pubmed_authors><pubmed_authors>Maes N</pubmed_authors><pubmed_authors>Albert A</pubmed_authors></additional><is_claimable>false</is_claimable><name>&lt;i>Curcuma longa&lt;/i> and &lt;i>Boswellia serrata&lt;/i> extract combination for hand osteoarthritis: an open-label pre-post trial.</name><description>&lt;h4>Context&lt;/h4>Osteoarthritis (OA) of the hand is a common painful musculoskeletal disorder with no cure. There is a need for an efficient and safe treatment to relieve OA pain.&lt;h4>Objective&lt;/h4>To investigate the effects of a &lt;i>Curcuma longa&lt;/i> and &lt;i>Boswellia serrata&lt;/i> food supplement in addition to standard care on hand pain.&lt;h4>Materials and methods&lt;/h4>This open-label, non-controlled, post-observational study was based on 232 patients suffering from hand pain with or without joint deformity. Patients received a medical prescription for a three-month treatment with a food supplement containing 89 mg of &lt;i>C. longa&lt;/i> dry extract, 120 mg of &lt;i>B. serrata&lt;/i> resin, and 1.8 µg vitamin D. Pain was evaluated on a 10-point visual analog scale (VAS). The number of painful hand joints, patient satisfaction, nonsteroidal anti-inflammatory drugs intake, and side effects were also recorded.&lt;h4>Results&lt;/h4>Baseline pain intensity (regression coefficient ± &lt;i>SE&lt;/i>: -0.19 ± 0.01, &lt;i>p&lt;/i> &lt; 0.0001) and the number of painful joints (regression coefficient ± &lt;i>SE&lt;/i>: -0.022 ± 0.0029, &lt;i>p&lt;/i> &lt; 0.0001) decreased significantly throughout the 3 months treatment period. NSAIDs intake and topical drug application were significantly decreased by 64% (&lt;i>p&lt;/i> &lt; 0.0001) and 79% (&lt;i>p&lt;/i> &lt; 0.0001) after 12 weeks, respectively. Only 3/239 (1.3%) patients reported side effects probably related to the product. 80.3% were satisfied with the treatment and 75.5% wished to continue treatment.&lt;h4>Conclusion&lt;/h4>This is the first clinical trial showing that &lt;i>C. longa&lt;/i> and &lt;i>B. serrata&lt;/i> resin can relieve symptoms in patients with hand osteoarthritis. The study provides useful information for the design of a clinical trial including a broader population.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-19T22:47:43.43Z</modification><creation>2025-04-19T22:47:43.43Z</creation></dates><accession>S-EPMC9704064</accession><cross_references><pubmed>36416059</pubmed><doi>10.1080/13880209.2022.2147550</doi></cross_references></HashMap>